News

Dry eye disease is notoriously underdiagnosed. It’s also a market with a strong upside potential. In a recent interview with OIS Weekly, internationally known anterior…

In ophthalmic innovation, great ideas only go so far. Without a potential revenue stream, investors would leave great ideas at the bench. In glaucoma, however,…

Late-stage biotech Tarsus Pharmaceuticals raised $88 million in its October NASDAQ debut. In announcing the close of its initial public offering, the company stated that…

Drug-delivery technologies typically aim to improve pharmacologic and therapeutic properties of already approved drugs, but pharmaceutical companies are sometimes hesitant to acquire, develop, or invest…

While scuba diving in the Caribbean, John Berdahl, MD, came up with the idea that led him to found Equinox. Five years later, that company…

Part 2 of 2 Micro-invasive glaucoma surgery (MIGS) has been in the forefront of innovation in the glaucoma space, and while MIGS innovation still has…

Part 1 of 2 The global COVID-19 pandemic has caused some changes in how companies in the glaucoma space pursue new products and technology, but…

Reporting positive top-line clinical trial results, initiating two other clinical trials, getting wider Medicare coverage of its lead product, resolving a regulatory warning letter, and…

Opthea, the Australia-based biopharma developing a novel therapy to treat exudative retinal diseases, closed out a busy summer with a US Securities and Exchange Commission…

“Never in the field of human conflict was so much owed by so many to so few” is a maxim you’re probably familiar with. Spoken…

As Outlook Therapeutics announced top-line results from the first of two registration clinical trials evaluating the safety and efficacy of its formulation of bevacizumab-vikg, ONS-5010,…

Product development in retina is a matter of suitors. That is, people looking for the right product development team to join, and early stage companies…